Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Phase 1 Completed 24 enrolled Novo Nordisk A/S

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.

Timeline

Start: 2006-03
Primary completion: 2006-06
Completion: 2006-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	0.75 mg	Subcutaneous

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

Summary

Timeline

Drugs

Indications